{"id":"placebo-galantamine-reminyl","safety":{"commonSideEffects":[{"rate":"13-24%","effect":"Nausea"},{"rate":"6-12%","effect":"Vomiting"},{"rate":"8-15%","effect":"Diarrhea"},{"rate":"5-9%","effect":"Dizziness"},{"rate":"8-17%","effect":"Headache"},{"rate":"5-10%","effect":"Abdominal pain"},{"rate":"5-9%","effect":"Anorexia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Galantamine is a reversible inhibitor of the enzyme acetylcholinesterase, which breaks down the neurotransmitter acetylcholine. By inhibiting this enzyme, galantamine increases acetylcholine concentration in the synaptic cleft, enhancing cholinergic neurotransmission. Additionally, galantamine acts as an allosteric modulator of nicotinic receptors, further potentiating cholinergic signaling and potentially providing neuroprotective effects.","oneSentence":"Galantamine inhibits acetylcholinesterase to increase acetylcholine levels in the brain, improving cognitive function in Alzheimer's disease.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:01:02.810Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Mild to moderate Alzheimer's disease"}]},"trialDetails":[{"nctId":"NCT00523666","phase":"PHASE4","title":"Diffusion Tensor Weighted MRI in Alzheimer's Disease Modifying Treatment Effects of Galantamine (Reminyl®)","status":"UNKNOWN","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2006-09","conditions":"Alzheimer's Disease","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Placebo/Galantamine (Reminyl®)","genericName":"Placebo/Galantamine (Reminyl®)","companyName":"Ludwig-Maximilians - University of Munich","companyId":"ludwig-maximilians-university-of-munich","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Galantamine inhibits acetylcholinesterase to increase acetylcholine levels in the brain, improving cognitive function in Alzheimer's disease. Used for Mild to moderate Alzheimer's disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}